ZNF574
gene geneOn this page
Also known as FLJ22059
Summary
ZNF574 (zinc finger protein 574, HGNC:26166) is a protein-coding gene on chromosome 19q13.2, encoding Zinc finger protein 574 (Q6ZN55). Part of a ribosome quality control that mediates surveillance of ribosome assembly and promotes degradation of ribosomes with assembly defects. It is a selective cancer dependency (DepMap: 72.0% of cell lines).
Predicted to enable DNA binding activity and zinc ion binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.
Source: NCBI Gene 64763 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 142 total
- Cancer dependency (DepMap): dependent in 72.0% of screened cell lines
- MANE Select transcript:
NM_022752
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26166 |
| Approved symbol | ZNF574 |
| Name | zinc finger protein 574 |
| Location | 19q13.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ22059 |
| Ensembl gene | ENSG00000105732 |
| Ensembl biotype | protein_coding |
| Entrez | 64763 |
Gene structure
Transcript identifiers
Ensembl transcripts: 7 — 7 protein_coding
ENST00000222339, ENST00000359044, ENST00000597391, ENST00000600245, ENST00000852237, ENST00000933758, ENST00000933761
RefSeq mRNA: 2 — MANE Select: NM_022752
NM_001330519, NM_022752
CCDS: CCDS12596, CCDS82356
Canonical transcript exons
ENST00000359044 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001510305 | 42076166 | 42076286 |
| ENSE00003046952 | 42078587 | 42081552 |
Expression profiles
Bgee: expression breadth ubiquitous, 277 present calls, max score 91.46.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.2892 / max 87.0869, expressed in 1797 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 176112 | 13.2892 | 1797 |
Top tissues by expression
288 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| type B pancreatic cell | CL:0000169 | 91.46 | gold quality |
| olfactory bulb | UBERON:0002264 | 91.38 | gold quality |
| cerebellar vermis | UBERON:0004720 | 89.84 | gold quality |
| right testis | UBERON:0004534 | 89.29 | gold quality |
| left testis | UBERON:0004533 | 89.09 | gold quality |
| oocyte | CL:0000023 | 89.08 | gold quality |
| vena cava | UBERON:0004087 | 89.06 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 88.16 | silver quality |
| parotid gland | UBERON:0001831 | 87.70 | gold quality |
| testis | UBERON:0000473 | 87.28 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 86.94 | silver quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 86.53 | gold quality |
| cervix squamous epithelium | UBERON:0006922 | 86.14 | silver quality |
| nipple | UBERON:0002030 | 85.68 | gold quality |
| body of tongue | UBERON:0011876 | 85.60 | gold quality |
| secondary oocyte | CL:0000655 | 85.55 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 85.51 | gold quality |
| inferior olivary complex | UBERON:0002127 | 85.49 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 85.31 | gold quality |
| male germ cell | CL:0000015 | 85.22 | gold quality |
| dorsal motor nucleus of vagus nerve | UBERON:0002870 | 85.04 | gold quality |
| dorsal plus ventral thalamus | UBERON:0001897 | 84.74 | gold quality |
| sperm | CL:0000019 | 84.47 | gold quality |
| subthalamic nucleus | UBERON:0001906 | 84.47 | gold quality |
| cardia of stomach | UBERON:0001162 | 84.32 | silver quality |
| tongue | UBERON:0001723 | 84.07 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 84.07 | gold quality |
| vastus lateralis | UBERON:0001379 | 83.58 | silver quality |
| pharyngeal mucosa | UBERON:0000355 | 83.05 | gold quality |
| heart right ventricle | UBERON:0002080 | 82.97 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 2.78 |
Regulation
Is transcription factor: yes
JASPAR motifs
| Motif | Name | Family |
|---|---|---|
| MA1982.1 | ZNF574 | Factors with multiple dispersed zinc fingers |
| MA1982.2 | ZNF574 | Factors with multiple dispersed zinc fingers |
JASPAR matrix evidence (PMIDs): PMID:22955616
miRNA regulators (miRDB)
18 targeting ZNF574, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-153-5P | 99.89 | 73.86 | 6317 |
| HSA-LET-7A-2-3P | 99.87 | 70.53 | 1921 |
| HSA-LET-7G-3P | 99.85 | 70.43 | 1929 |
| HSA-MIR-4639-5P | 99.81 | 67.37 | 1028 |
| HSA-MIR-92A-2-5P | 99.75 | 67.01 | 2164 |
| HSA-MIR-1825 | 99.72 | 68.11 | 1089 |
| HSA-MIR-29B-2-5P | 99.67 | 68.98 | 1726 |
| HSA-MIR-3202 | 99.66 | 67.70 | 2737 |
| HSA-MIR-6134 | 99.63 | 65.68 | 1537 |
| HSA-MIR-3123 | 99.47 | 67.15 | 2693 |
| HSA-MIR-5683 | 99.36 | 68.59 | 2083 |
| HSA-MIR-4291 | 99.20 | 68.88 | 2969 |
| HSA-MIR-622 | 98.99 | 66.48 | 1050 |
| HSA-MIR-12114 | 98.70 | 63.45 | 730 |
| HSA-MIR-3085-5P | 97.72 | 65.43 | 544 |
| HSA-MIR-9851-5P | 97.57 | 67.49 | 1067 |
| HSA-MIR-4264 | 96.35 | 64.76 | 1480 |
| HSA-MIR-6777-3P | 95.35 | 64.30 | 699 |
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 72.0% of screened cell lines.
Literature-anchored findings (GeneRIF, showing 1)
- ZNF574 Promotes Ovarian Cancer Cell Proliferation and Migration through Regulating AKT and AMPK Signaling Pathways. (PMID:36197766)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | zgc:66472 | ENSDARG00000075916 |
| mus_musculus | Zfp574 | ENSMUSG00000045252 |
| rattus_norvegicus | Zfp574 | ENSRNOG00000055761 |
| drosophila_melanogaster | mld | FBGN0263490 |
Paralogs (36): ZNF302 (ENSG00000089335), ZNF184 (ENSG00000096654), CTCF (ENSG00000102974), ZBTB24 (ENSG00000112365), ZNF142 (ENSG00000115568), CTCFL (ENSG00000124092), ZNF473 (ENSG00000142528), ZNF827 (ENSG00000151612), ZNF689 (ENSG00000156853), ZNF208 (ENSG00000160321), ZNF91 (ENSG00000167232), ZNF526 (ENSG00000167625), ZNF764 (ENSG00000169951), ZNF747 (ENSG00000169955), ZNF282 (ENSG00000170265), ZNF160 (ENSG00000170949), ZNF497 (ENSG00000174586), ZBTB34 (ENSG00000177125), ZNF771 (ENSG00000179965), ZNF48 (ENSG00000180035), ZNF594 (ENSG00000180626), ZBTB37 (ENSG00000185278), ZFP92 (ENSG00000189420), ZNF107 (ENSG00000196247), ZNF729 (ENSG00000196350), ZNF569 (ENSG00000196437), ZNF420 (ENSG00000197050), ZNF785 (ENSG00000197162), ZNF665 (ENSG00000197497), ZNF181 (ENSG00000197841), ZNF347 (ENSG00000197937), ZNF84 (ENSG00000198040), ZBTB48 (ENSG00000204859), ZNF845 (ENSG00000213799), ZNF99 (ENSG00000213973), ZNF688 (ENSG00000229809)
Protein
Protein identifiers
Zinc finger protein 574 — Q6ZN55 (reviewed: Q6ZN55)
All UniProt accessions (3): Q6ZN55, A0A0C4DFM2, M0R133
UniProt curated annotations — full annotation on UniProt →
Function. Part of a ribosome quality control that mediates surveillance of ribosome assembly and promotes degradation of ribosomes with assembly defects.
Subunit / interactions. Associates with defective pre-ribosomes.
Subcellular location. Cytoplasm. Nucleus.
Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q6ZN55-1 | 1 | yes |
| Q6ZN55-2 | 2 |
RefSeq proteins (2): NP_001317448, NP_073589* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR013087 | Znf_C2H2_type | Domain |
| IPR036236 | Znf_C2H2_sf | Homologous_superfamily |
| IPR050636 | C2H2-ZF_domain-containing | Family |
Pfam: PF00096, PF12874, PF13912
UniProt features (40 total): zinc finger region 20, modified residue 7, region of interest 3, compositionally biased region 3, sequence variant 3, sequence conflict 2, chain 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6ZN55-F1 | 63.54 | 0.08 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (7): 113, 164, 298, 717, 724, 728, 832
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 114 (showing top):
GOBP_RIBOSOME_BIOGENESIS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_RIBOSOME_ASSEMBLY, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, MARTINEZ_RB1_TARGETS_UP, MARTINEZ_RB1_TARGETS_DN, GOBP_ORGANELLE_ASSEMBLY, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_TRANS, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOBP_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEOLYSIS, GOMF_RIBONUCLEOPROTEIN_COMPLEX_BINDING, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOMF_RIBOSOME_BINDING
GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), developmental process (GO:0032502)
GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (1): nucleus (GO:0005634)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of DNA-templated transcription | 1 |
| transcription by RNA polymerase II | 1 |
| biological_process | 1 |
| nucleic acid binding | 1 |
| transition metal ion binding | 1 |
| binding | 1 |
| cation binding | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
892 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZNF574 | TMEM145 | Q8NBT3 | 582 |
| ZNF574 | CNFN | Q9BYD5 | 549 |
| ZNF574 | CEACAM7 | Q14002 | 526 |
| ZNF574 | PAFAH1B3 | Q15102 | 525 |
| ZNF574 | MANBAL | Q9NQG1 | 490 |
| ZNF574 | PLEKHJ1 | Q9NW61 | 477 |
| ZNF574 | TRMT1L | Q7Z2T5 | 451 |
| ZNF574 | PRR19 | A6NJB7 | 447 |
| ZNF574 | TRMT10A | Q8TBZ6 | 433 |
| ZNF574 | PSG11 | Q9UQ72 | 411 |
| ZNF574 | ZNF512 | Q96ME7 | 407 |
| ZNF574 | PSG6 | Q00889 | 405 |
| ZNF574 | NAA38 | Q9BRA0 | 396 |
| ZNF574 | PSG4 | Q00888 | 392 |
| ZNF574 | PSG1 | P11462 | 391 |
| ZNF574 | TOMM40L | Q969M1 | 391 |
IntAct
95 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| LARP7 | CCNT1 | psi-mi:“MI:0914”(association) | 0.850 |
| GPR156 | PLD2 | psi-mi:“MI:0914”(association) | 0.640 |
| LIN28A | IGF2BP3 | psi-mi:“MI:0914”(association) | 0.640 |
| THAP12 | ZNF574 | psi-mi:“MI:0915”(physical association) | 0.620 |
| ZNF574 | THAP12 | psi-mi:“MI:0914”(association) | 0.620 |
| N | NOP56 | psi-mi:“MI:0914”(association) | 0.530 |
| RPS3 | ZNF316 | psi-mi:“MI:0914”(association) | 0.530 |
| MAGEB2 | POLRMT | psi-mi:“MI:0914”(association) | 0.530 |
| ZNF689 | ZNF593 | psi-mi:“MI:0914”(association) | 0.530 |
| RPS2 | MPHOSPH10 | psi-mi:“MI:0914”(association) | 0.530 |
| ZC3HAV1 | KHNYN | psi-mi:“MI:0914”(association) | 0.530 |
| E4F1 | ZBTB24 | psi-mi:“MI:0914”(association) | 0.530 |
| XAGE1A | THAP12 | psi-mi:“MI:0914”(association) | 0.530 |
| NIFK | RSL1D1 | psi-mi:“MI:0914”(association) | 0.530 |
| RPSA | RPS17 | psi-mi:“MI:0914”(association) | 0.530 |
| ABT1 | ZNF316 | psi-mi:“MI:0914”(association) | 0.530 |
| MAGEB2 | GTPBP10 | psi-mi:“MI:0914”(association) | 0.530 |
| ZNF574 | E2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ZNF574 | E7 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ZNF526 | VAMP4 | psi-mi:“MI:0914”(association) | 0.350 |
| Set | ZKSCAN1 | psi-mi:“MI:0914”(association) | 0.350 |
| ESR1 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| rl3_rl3l_human | NKRF | psi-mi:“MI:0914”(association) | 0.350 |
| rl36a_rl36l_human | IPO5 | psi-mi:“MI:0914”(association) | 0.350 |
| IGHM | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| RPS19 | ZNF320 | psi-mi:“MI:0914”(association) | 0.350 |
| PURG | ZNF320 | psi-mi:“MI:0914”(association) | 0.350 |
| ZNF467 | ZNF320 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (301): ZNF574 (Affinity Capture-MS), ZNF574 (Affinity Capture-MS), ZNF574 (Affinity Capture-MS), ZNF574 (Affinity Capture-MS), ZNF574 (Affinity Capture-MS), ZNF574 (Affinity Capture-MS), ZNF574 (Reconstituted Complex), ZNF574 (Affinity Capture-MS), ZNF574 (Affinity Capture-MS), ZNF574 (Affinity Capture-MS), ZNF574 (Affinity Capture-MS), SHCBP1 (Affinity Capture-MS), PRKRIR (Affinity Capture-MS), TRIM41 (Affinity Capture-MS), ANKRD28 (Affinity Capture-MS)
ESM2 similar proteins: A2A5K6, A6QR00, D4A8X0, E9Q6W4, G3V893, O15015, O15156, O95863, P0CJ78, P10074, Q02085, Q13105, Q29RK0, Q3U3I9, Q4R8S8, Q504L7, Q5EBL2, Q5F293, Q5R4P8, Q5RJR4, Q60821, Q66K89, Q6DD87, Q6GL52, Q6NV66, Q6PGE4, Q6YND2, Q6ZN55, Q80VM4, Q8BI66, Q8BI69, Q8BIF9, Q8BY46, Q8CCE9, Q8CJ78, Q8JZL0, Q8N1W2, Q8NCA9, Q8TF50, Q8WUU4
Diamond homologs: A1L2U9, A2A884, A2ANX9, A7Y7X5, B0X9H6, B0YDH7, B1WAZ8, B1WBU4, E9PW05, E9PZZ1, G5EBU4, O15391, O60315, O62836, O75362, O77459, O95863, P08048, P0CS62, P0CS63, P10925, P15822, P17010, P17012, P20662, P22227, P25490, P28166, P31509, P31629, P36197, P52739, P52746, P56270, P56670, P56671, P60319, P80944, Q00899, Q00900
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 106 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| SARS-CoV-1 modulates host translation machinery | 10 | 53.2× | 4e-14 |
| Eukaryotic Translation Initiation | 9 | 47.9× | 2e-12 |
| Cap-dependent Translation Initiation | 9 | 47.9× | 2e-12 |
| Eukaryotic Translation Elongation | 9 | 43.2× | 4e-12 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 9 | 42.2× | 5e-12 |
| Influenza Viral RNA Transcription and Replication | 10 | 37.1× | 1e-12 |
| Nonsense-Mediated Decay (NMD) | 9 | 36.2× | 2e-11 |
| SARS-CoV-2 modulates host translation machinery | 9 | 34.8× | 3e-11 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| cytoplasmic translation | 14 | 28.8× | 2e-14 |
| ribosomal small subunit biogenesis | 10 | 25.3× | 8e-10 |
| regulation of alternative mRNA splicing, via spliceosome | 8 | 21.7× | 3e-07 |
| rRNA processing | 11 | 17.3× | 4e-09 |
| translation | 13 | 14.8× | 8e-10 |
| RNA splicing | 7 | 6.9× | 3e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
142 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 137 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
468 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 19:42078585:A:AG | acceptor_gain | 1.0000 |
| 19:42078586:G:GA | acceptor_gain | 1.0000 |
| 19:42078586:GC:G | acceptor_gain | 1.0000 |
| 19:42078586:GCCC:G | acceptor_gain | 1.0000 |
| 19:42078586:GCCCA:G | acceptor_gain | 1.0000 |
| 19:42078572:T:A | acceptor_gain | 0.9900 |
| 19:42078586:GCC:G | acceptor_gain | 0.9900 |
| 19:42070967:C:T | donor_gain | 0.9700 |
| 19:42078570:ACT:A | acceptor_gain | 0.9600 |
| 19:42078571:C:G | acceptor_gain | 0.9600 |
| 19:42070905:G:GT | donor_gain | 0.9500 |
| 19:42070803:A:G | donor_gain | 0.9400 |
| 19:42070939:C:T | donor_gain | 0.9300 |
| 19:42076129:G:GT | donor_gain | 0.9300 |
| 19:42078570:A:AG | acceptor_gain | 0.9300 |
| 19:42070789:A:T | donor_gain | 0.9200 |
| 19:42076130:A:T | donor_gain | 0.9200 |
| 19:42070869:G:GT | donor_gain | 0.9100 |
| 19:42070870:G:T | donor_gain | 0.9100 |
| 19:42078581:TTCCA:T | acceptor_gain | 0.9000 |
| 19:42078582:TCCAG:T | acceptor_gain | 0.9000 |
| 19:42078583:CCAGC:C | acceptor_gain | 0.9000 |
| 19:42078584:CAGC:C | acceptor_gain | 0.9000 |
| 19:42078585:A:C | acceptor_gain | 0.9000 |
| 19:42078586:G:T | acceptor_gain | 0.9000 |
| 19:42076282:AGCAG:A | donor_loss | 0.8800 |
| 19:42076284:CAGGT:C | donor_loss | 0.8800 |
| 19:42076285:AGG:A | donor_loss | 0.8800 |
| 19:42076286:GG:G | donor_loss | 0.8800 |
| 19:42076287:GTGAG:G | donor_loss | 0.8800 |
AlphaMissense
5740 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 19:42080179:T:C | C525R | 1.000 |
| 19:42080284:T:C | F560L | 1.000 |
| 19:42080285:T:C | F560S | 1.000 |
| 19:42080286:C:A | F560L | 1.000 |
| 19:42080286:C:G | F560L | 1.000 |
| 19:42080908:T:C | C768R | 1.000 |
| 19:42080929:T:C | F775L | 1.000 |
| 19:42080931:C:A | F775L | 1.000 |
| 19:42080931:C:G | F775L | 1.000 |
| 19:42081013:T:C | F803L | 1.000 |
| 19:42081014:T:C | F803S | 1.000 |
| 19:42081015:T:A | F803L | 1.000 |
| 19:42081015:T:G | F803L | 1.000 |
| 19:42081076:T:C | C824R | 1.000 |
| 19:42078988:T:C | C128R | 0.999 |
| 19:42079009:T:C | F135L | 0.999 |
| 19:42079010:T:C | F135S | 0.999 |
| 19:42079011:T:A | F135L | 0.999 |
| 19:42079011:T:G | F135L | 0.999 |
| 19:42079274:T:C | F223S | 0.999 |
| 19:42079618:T:C | C338R | 0.999 |
| 19:42079786:T:C | C394R | 0.999 |
| 19:42079804:T:C | F400L | 0.999 |
| 19:42079806:T:A | F400L | 0.999 |
| 19:42079806:T:G | F400L | 0.999 |
| 19:42080008:T:C | C468R | 0.999 |
| 19:42080095:T:C | C497R | 0.999 |
| 19:42080181:C:G | C525W | 0.999 |
| 19:42080188:T:C | C528R | 0.999 |
| 19:42080190:C:G | C528W | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000238800 (19:42068839 G>A), RS1000480941 (19:42081351 A>G), RS1000571702 (19:42069746 G>A,T), RS1000800980 (19:42075327 G>A), RS1000853440 (19:42075577 G>T), RS1000904965 (19:42075167 G>A,C), RS1001063205 (19:42069325 G>A,T), RS1001220306 (19:42066526 G>A), RS1001315755 (19:42074448 C>T), RS1001410872 (19:42069148 G>A,T), RS1001475908 (19:42077949 G>A), RS1001504705 (19:42069498 G>A), RS1001529736 (19:42078276 G>A,T), RS1001740574 (19:42071791 G>A), RS1001807824 (19:42076464 C>T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST010143_27 | Meat-related diet | 3.000000e-09 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0008111 | diet measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
26 total (human), top 26 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| aristolochic acid I | increases expression | 1 |
| 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide | decreases expression | 1 |
| FR900359 | decreases phosphorylation | 1 |
| TAK-243 | increases sumoylation | 1 |
| sodium arsenite | decreases expression | 1 |
| potassium chromate(VI) | increases expression, affects cotreatment | 1 |
| epigallocatechin gallate | affects cotreatment, increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| abrine | increases expression | 1 |
| PCI 5002 | increases expression, affects cotreatment | 1 |
| Irinotecan | decreases expression | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Arsenic | affects methylation | 1 |
| Diuron | decreases expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
| Potassium Chloride | decreases response to substance, increases expression | 1 |
| Smoke | decreases expression | 1 |
| Dronabinol | increases expression, decreases response to substance | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Valproic Acid | increases methylation | 1 |
| Zinc | affects cotreatment, increases expression | 1 |
| Cyclosporine | increases expression | 1 |
| Antirheumatic Agents | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.